

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/201299 A1

(51) International Patent Classification:

A61K 31/4196 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/IB2024/052897

(22) International Filing Date:

26 March 2024 (26.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/492,396	27 March 2023 (27.03.2023)	US
63/502,076	12 May 2023 (12.05.2023)	US
63/505,613	01 June 2023 (01.06.2023)	US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **CHAKRAVARTTY, Arunava**; Novartis
Pharmaceuticals Corporation, 59 Route 10, East Hanover,
New Jersey 07936 (US). **LI, Zheng**; Novartis Pharmaceu-
ticals Corporation, 59 Route 10, East Hanover, New Jer-
sey 07936 (US). **TARAN, Tetiana**; Novartis Pharma AG,
Lichtstrasse 35, 4056 Basel (CH). **ZARATE, Juan Pablo**;
Novartis Pharmaceuticals Corporation, 59 Route 10, East
Hanover, New Jersey 07936 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: METHOD OF TREATING EARLY BREAST CANCER WITH RIBOCICLIB IN COMBINATION WITH AN AROMATASE INHIBITOR

(57) Abstract: The present disclosure relates to the adjuvant treatment of HR+/HER2- stage II or III early breast cancer in adult patients. The method includes administering ribociclib (a CDK4/6 inhibitor) in combination with endocrine therapy.

WO 2024/201299 A1